Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3977)	6/3/2001 10:35:09 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Miljenko, <<Aberelix>> Well I hope you're wrong on this one, because I'm holding on for now. Certainly an allergic reaction to something in a depot formulation could potentially be a significant concern - no way to remove the allergen. It's hard to know how the TAP/ABBT issue plays here. On the one hand prices for Lupron will likely come down some, on the other they'll have to play fair in marketing. On ATRX, this from a recent report: >>an NDA submitted for the 30-day formulation of Leuprogel, the 90-day formulation NDA on track to file in Q4:01<< Peter